Issues in nonoperative management of locally advanced non-small-cell lung cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL. 2, 1998, Pages 60-66

  Curran Jr , Walter J ^a   Werner Wasik, Maria ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; VINBLASTINE; VINBLASTINE SULFATE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; RADIATION DOSE FRACTIONATION; RADIATION ENTEROPATHY; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FORECASTING; HUMANS; LUNG NEOPLASMS;

EID: 6844257525     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Mountain CF, Dressler CM: Regional lymph node classification for lung cancer staging. Chest 111:1718-1723, 1997.
2. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997 CA Cancer J Chin 47:5-27, 1997.
3. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat-cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59:1874-1881, 1987.
4. Johnson DW, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced unresected non-small-cell lung cancer. Ann Intern Med 113:33-38, 1990.
5. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer 45:2744-2753, 1980.
6. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83-417-423, 1991.
7. King SC, Acker JC, Kussin PS, et al: High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of non-small-cell lung cancer: Unusual toxicity and promising early results Int J Radiat Oncol Biol Phys 36:593-599, 1996.
8. Emami B, Scott C, Byhardt R, et al. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small-cell lung cancer: An RTOG analysis. Int J Radiat Oncol Biol Phys 36:209, 1996.
9. Fletcher G: Clinical dose-response curves of human malignant epithelial tumors. Br J Radiol 46:1-12, 1973.
10. Huber RM, Fischer R, Hautmann H, et al: Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 38:533-540, 1997.
11. Slotman BJ, Njo KH, Karim A BMP: Curative radiotherapy for technically operable stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 29:33-37, 1994.
12. Dosoretz DE, Galmarini D, Rubenstein JH, et al: Local control in medically inoperable lung cancer: An analysis of its importance in outcome and factors determining the probability of tumor eradication Int J Radiat Oncol Biol Phys 27:507-516, 1993.
13. Kaskowitz L, Graham MV, Emami B, et al: Radiation therapy alone for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 27:517-523, 1993.
14. Graham PH, Gebski VJ, Stat M, et al. Radical radiotherapy for early non-small-cell lung cancer. lnt J Radiat Oncol Biol Phys 31:261-266, 1995.
15. Sandler HM, Curran WJ, Turrisi AT: The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 19:9-13, 1990.
16. Noordijk EM, Poest C, Evd Wever AMJ, et al: Radiotherapy as an alternative to surgery in elderly patients with reseetable lung cancer Radiother Oncol 13:83-89, 1988.
17. Kupelian PA, Komaki R, Allen P: Prognostic factors in the treatment of node-negative non-small-cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 36:607-613, 1996.
18. Cox JD, Azarina N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 0 Gy to 79.2 Gy: Possible survival benefit with > 69.6 Gy in favorable patients with stage III non-small-cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990.
19. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small-cell lung cancer. Cancer 75:2337-2344, 1995.
20. Sause W, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (FCOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
21. Hermens AF, Barendsen GW: Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after X-irradiation. Eur J Cancer 5:173-189, 1969.
22. Saunders MI, Dische S. Barrett A, et al: Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Br J Cancer 73:1455-1462, 1996
23. Tannehill SP, Froseth C, Wagner H, et al: A multi-institutional phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small-cell lung cancer: Initial report of ECOG 4593. Int J Radiat Oncol Biol Phys 36:207, 1996.
24. Slawson RG, Scott RM: Radiation therapy in bronchogenic carcinoma Radiology 132:175-176, 1979.
25. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25-32, 1980.
26. Lutz ST, Huang DT, Ferguson CL, et al: A retrospective quality of life analysis using the Lung Cancer Symptom scale in patients treated with palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 37:117-122, 1997.
27. Kris MG, Gralla RJ, Potanovich LM, et al: Assessment of pre-treatment symptoms and improvement after EDAM + mitomycin + vinblastine in patients with inoperable non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 9:229, 1990.
28. Macbeth FR, Bolger JJ, Hopwood P, et al: Randomized trial of palliative two fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small-cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party Clin Oncol (R Coll Radiol) 8:167-175, 1996.
29. Paesmans M, Sculier JP, Libert G, et al: Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13:1221-1230, 1995.
30. Dillman RO, Seagren SL, Herndon J, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990.
31. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer. Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
32. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy in inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992.
33. McGinnis WL, Shaw EG, Jung S-H, et al: Results of a phase III prospective randomized trial comparing standard thoracic radiation therapy (RT) to twice daily RT+/-concomitant etoposide/cisplatin chemotherapy in patients with unresectable stage IIIA/B non-small-cell lung cancer (abstract 1079). Proc Am Soc Clin Oncol 14:355, 1995.
34. Sause WT, Scott C, Taylor et al: Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 15:163-167, 1992.
35. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small-cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477-482, 1988.
36. Trovo MG, Minatel E, Franchi G, et al: Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 24:11-15, 1992.
37. Blanke C, Ansari R, Mantravadi R, et al: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group protocol. J Clin Oncol 13:1425-1429, 1995.
38. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone vs. combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: A meta-analysis. Cancer 76:593-601, 1995.
39. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated individual patients data from 52 randomized clinical trials. Br Med 7311:899-909, 1995.
40. Pignon JP: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: A meta-analysis. Cancer 77:2413-2414, 1996.
41. Lee JS, Scott CB, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064, 1996
42. Jeremic B, Shibaraoto Y, Aciraovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study J Clin Oncol 14:1065-1070, 1996.
43. Perez CA, Stanley K, Grundy G: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat-cell carcinoma of the lung. Cancer48101-48109, 1982.
44. Curran WJ, Moldofsky PH, Solin LJ: Analysis of the influence of elective nodal irradiation on postirradiation pulmonary function. Cancer 65:2488-2493, 1990.
45. Byhardt RW, Martin L, Pajak TF, et al: The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small-cell lung cancer (NSCLC)-Analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 27:537-544, 1993.
46. Oetzel D, Schraube P, Hensley F, et al: Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:455-460, 1995.
47. Krol A, Aussems P, Noordijk EM, et al: Local irradiation alone for peripheral stage I lung cancer. Could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 34:297-302, 1996.
48. Emami B: Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiation Oncol 6:92-97, 1996.
49. Graham MV, Matthews IW, Harms WB, et al: Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys 29:1105-1117, 1994.
50. Graham MV, Shiue K, Emami B, et al: Dose-volume correlations with early pneumonitis for #D treatment planning for non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys (in press)
51. Passlick B, Izbicki JR, Kubuschok B, et al: Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 12:1827-1832, 1994.
52. Vansant JP, Johnson DH, O'Donnell DM, et al: Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clin Nucl Med 17:431-438, 1992.
53. Takekawa H, Takaoka K, Tsukamoto E, et al: Thallium 201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma. Cancer 80:198-204, 1997.
54. Frank A, Lefkowitz D, Jaeger S, et al: Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32:1495-1512, 1995.